Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Operating expenses
Research and development	$ 6,695	$ 2,760
General and administrative	2,003	2,012
Change in fair value of contingent consideration	584	206
Total operating expenses	9,282	4,978
Operating loss	(9,282)	(4,978)
Other income (expense)
Change in fair value of warrants liabilities	3,413	(1,919)
Loss from minority interest investment		(190)
Interest income	11	57
Total other income (expense)	3,424	(2,052)
Net loss	$ (5,858)	$ (7,030)
Net loss per common share, basic and diluted	$ (0.13)	$ (0.22)
Weighted-average common shares outstanding used to calculate basic and diluted net loss per common share	44,679,858	31,756,120